Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCPF0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,868
Award facts
- Contract value 100% obligated
- $18,868.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $18,868.32 to DMS Pharmaceutical Group Inc. for Trikafta 100-50-75 mg/150 mg pharmaceutical product, with an ultimate completion date of December 31, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order represents part of DMS Pharmaceutical Group's ongoing pharmaceutical supply relationship with the Defense Logistics Agency's Medical Supply Chain division.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a ceiling value of $499,999,999 and completion date of December 31, 2036. The PPV-G GEN V contract positions DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion acquisition strategy designed to supply branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support Department of Defense healthcare operations globally. The company's established performance across diverse pharmaceutical categories demonstrates its capability to fulfill specialized medical supply requirements for military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FCPF0?
SPE2DR26FCPF0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 30, 2025.
How much is contract SPE2DR26FCPF0 worth?
The government has obligated $18,868 on SPE2DR26FCPF0.
Is contract SPE2DR26FCPF0 an order under another contract?
Yes. SPE2DR26FCPF0 is a delivery order under SPE2DR25D9131, an indefinite delivery contract.
Was contract SPE2DR26FCPF0 competed?
The extent of competition for SPE2DR26FCPF0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award